Cargando…

Do preexisting antibodies against seasonal coronaviruses have a protective role against SARS-CoV-2 infections and impact on COVID-19 severity?

Detalles Bibliográficos
Autor principal:	Nasrallah, Gheyath K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783954/ https://www.ncbi.nlm.nih.gov/pubmed/35081490 http://dx.doi.org/10.1016/j.ebiom.2022.103831

Ejemplares similares

Is preexisting immunity to seasonal coronaviruses limited to cross-reactivity with SARS-CoV-2? A seroprevalence cross-sectional study in north-eastern France
por: Zedan, Hadeel T., et al.
Publicado: (2021)

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing
por: Muthumani, Kar, et al.
Publicado: (2021)

Seasonal coronaviruses and SARS-CoV-2: effects of preexisting immunity during the COVID-19 pandemic
por: WANG, Gang, et al.
Publicado: (2022)

A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2
por: Majdoubi, Abdelilah, et al.
Publicado: (2021)

The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: A systematic review
por: Al-Sadeq, Duaa W., et al.
Publicado: (2020)

Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients
por: Ruetalo, Natalia, et al.
Publicado: (2021)

Can Antibodies Protect Us Against Cardiovascular Disease?
por: Nilsson, Jan
Publicado: (2016)

The potential of developing a protective peptide‐based vaccines against SARS‐CoV‐2
por: Shalash, Ahmed O., et al.
Publicado: (2022)

No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults
por: Ercanoglu, Meryem Seda, et al.
Publicado: (2022)

Oracle or false prophet? Can we predict AAV efficacy based on preexisting antibody titers?
por: Anguela, Xavier M., et al.
Publicado: (2019)

SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

A pangolin-origin SARS-CoV-2-related coronavirus: infectivity, pathogenicity, and cross-protection by preexisting immunity
por: Huang, Xing-Yao, et al.
Publicado: (2023)

Effectiveness of mRNA booster doses against the omicron variant
por: Zedan, Hadeel T, et al.
Publicado: (2022)

Antibody titers against SARS-CoV-2 decline, but do not disappear for several months
por: Yamayoshi, Seiya, et al.
Publicado: (2021)

Do Animals Play a Role in the Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)? A Commentary
por: Costagliola, Anna, et al.
Publicado: (2020)

Compulsory Immunization Protects Against Infection: What Law and Society Can Do
por: Mehlman, Maxwell J., et al.
Publicado: (2020)

Timely development of vaccines against SARS-CoV-2
por: Lu, Shan
Publicado: (2020)

Coronavirus vaccine protects against SARS
Publicado: (2013)

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection
por: Anderson, Elizabeth M., et al.
Publicado: (2020)

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection
por: Anderson, Elizabeth M., et al.
Publicado: (2021)

Early seasonal coronavirus seroconversion did not produce cross-protective SARS-CoV-2 antibodies
por: Wong, Lydia Su Yin, et al.
Publicado: (2023)

The gift of preexisting immunity for developing an alternative vaccine strategy
por: Tran, Kim A., et al.
Publicado: (2023)

Do Human Milk Oligosaccharides Protect Against Infant Atopic Disorders and Food Allergy?
por: Han, Soo Min, et al.
Publicado: (2020)

Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2
por: Younes, Nadin, et al.
Publicado: (2020)

Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study”
por: Joyner, Michael J., et al.
Publicado: (2022)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
por: Jiang, Shibo, et al.
Publicado: (2020)

Distinct antibody repertoires against endemic human coronaviruses in children and adults
por: Khan, Taushif, et al.
Publicado: (2021)

Dissecting antibody-mediated protection against SARS-CoV-2
por: Zohar, Tomer, et al.
Publicado: (2020)

RNA interference as a promising treatment against SARS-CoV-2
por: Donia, Ahmed, et al.
Publicado: (2020)

Genomic surveillance of SARS-CoV-2: A race against time
por: Romano, Camila M, et al.
Publicado: (2021)

Severe acute respiratory syndrome coronavirus‐2 natural animal reservoirs and experimental models: systematic review
por: Younes, Salma, et al.
Publicado: (2020)

Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection
por: Abou-Saleh, Haissam, et al.
Publicado: (2022)

Duration of immune protection of SARS-CoV-2 natural infection against reinfection
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

Differential abundance of IgG antibodies against the spike protein of SARS-CoV-2 and seasonal coronaviruses in patients with fatal COVID-19
por: Smit, Wouter L., et al.
Publicado: (2023)

Antibodies Are Major Drivers of Protection against Lethal Aerosol Infection with Highly Pathogenic Burkholderia spp.
por: Hogan, Robert J., et al.
Publicado: (2019)

Do Myositis-Specific Antibodies have Specific Histopathological Marks?
por: Katirji, Bashar
Publicado: (2023)

Childhood vaccination against seasonal influenza – is there a risk of undesirable outcomes?
por: Baguelin, Marc, et al.
Publicado: (2020)

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Vaccine against SARS-CoV-2 in previously infected health care workers
por: Parisi, Saverio Giuseppe
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_voms0nqk8ervnrb0p9i3vg35iv